Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Manx Financial Group impresses with H1 guidance, Fiinu collab

(Sharecast News) - Shares in AIM-listed Manx Financial Group jumped on Tuesday afternoon after the financial services firm guided to a big jump in first-half profits and announced a new collaboration with fintech Fiinu. Manx, which operates FX and international payments outfit MFX and banking group Conister, released a short statement providing advance guidance for its results for the six months to 30 June, which are due out next Monday.

Manx said it expects to report a pre-tax profit of £4.1m for the period, up 16% from the £3.5m reported the year before.

Manx also reported earlier in the day that Conister Bank had entered into an exclusive agreement with Fiinu to introduce an "innovative overdraft product" in the UK.

The deal, which is subject to regulatory approval, will see Conister offer Fiinu's so-called Plugin Overdraft, an open banking technology that will allow customers of any UK bank to 'plugin' a Conister Bank overdraft to their primary current account without the need to switch banks.

"Fiinu's technology complements our strategic vision and will enable us to serve customers who are being overlooked by mainstream banking, thereby reinforcing our premier position as the specialist deposit taker and lender in the Isle of Man and UK," said Manx chief executive Douglas Grant, who also serves as Conister's managing director.

Fiinu's shares were down 13.6% at 13.4p by 1441 BST, while Manx was up nearly 5% at 37.1p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.